Effects of Evolocumab on Low-Density Lipoprotein Cholesterol, Non-High Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a) by Race and Ethnicity: A Meta-Analysis of Individual Participant Data From Double-Blind and Open-Label Extension Studies

RECOMMENDED

Lipid-Lowering Drugs

Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

J Am Heart Assoc.

Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M

doi: 10.1161/JAHA.119.014129.

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs

Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

J Am Heart Assoc.

Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP

doi: 10.1161/JAHA.117.005639.

Lipid-Lowering Drugs

Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

Circulation

Toth PP, Descamps O, Genest J, Sattar N, Preiss D, Dent RE, Djedjos CS, Wu Y, Geller M, Uhart M, Somaratne R, Wasserman SM; PROFICIO Investigators

doi: 10.1161/CIRCULATIONAHA.

Lipid-Lowering Drugs

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

JAMA Cardiol.

Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H, Ruzza A, Ma Y, Somaratne R, Raal FJ

doi: 10.1001/jamacardio.

Lipid-Lowering Drugs

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis

JAMA Cardiol.

Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP

doi: 10.1001/jamacardio.2018.2258

RECOMMENDED

Lipid-Lowering Drugs

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial

★ 3 Recommended by Prof. Dr Isabella Sudano, Faculty Member

JAMA.

Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB

doi: 10.1001/jama.2019.16585.

Lipid-Lowering DrugsTherapy and Intervention

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

JAMA Cardiol.

Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS

doi: 10.1001/jamacardio.

Cardiovascular Risk and DiseasesLipid-Lowering Drugs

Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study

Eur Heart J.

Penson PE, Long DL, Howard G, Toth PP, Muntner P, Howard VJ, Safford MM, Jones SR, Martin SS, Mazidi M, Catapano AL, Banach M

doi: 10.1093/eurheartj/ehy533.

COMMENTED

Lipid-Lowering Drugs

Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting

Eur Heart J.

Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG

doi: 10.1093/eurheartj/ehy334.

Related content

Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies

Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials

Pooled Safety Analysis of Evolocumab in Over 6000 Patients from Double-Blind and Open-label Extension Studies

Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study

Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis

Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study

Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting